Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population

Tamoore Arshad, Pegah Golabi, James Paik, Alita Mishra, Zobair M Younossi, Tamoore Arshad, Pegah Golabi, James Paik, Alita Mishra, Zobair M Younossi

Abstract

There is a paucity of recent data about the epidemiology and long-term outcomes of nonalcoholic fatty liver disease (NAFLD) in the female population. Our aim was to assess the prevalence, risk factors, and mortality of NAFLD in female adults of the United States. Data from the National Health and Nutrition Examination Survey (NHANES) III and NHANES 1999-2014 were used. NAFLD status was determined by the U.S. Fatty Liver Index (US-FLI) in the absence of other liver diseases and excessive alcohol consumption. The prevalence rates, risk factors, and 5-year all-cause and cardiovascular mortality were determined in women with NAFLD. The most recent prevalence of NAFLD among female adults (2007-2014) in the United States was 24.4% (95% confidence interval [CI], 22.48-26.33). Prevalence was higher among women >44 years of age and those with body mass index ≥30 kg/m2. In addition, the average age of the female population with NAFLD has decreased over time. The fully adjusted odds ratios in women with NAFLD compared to those without NAFLD were 1.48 (95% CI, 1.20-1.82) for cardiovascular disease (CVD), 1.89 (95% CI, 1.42-2.52) for atherosclerotic cardiovascular disease (ASCVD) score ≥7.5%, and 1.76 (95% CI, 1.37-2.25) for either CVD or ASCVD ≥7.5%. The 5-year mortality for female adults with NAFLD was significantly higher than for those without NAFLD (adjusted hazard ratio, 1.48; 95% CI, 1.07-2.05). Among women with NAFLD, those with ASCVD ≥7.5% had significantly higher 5-year all-cause mortality and CVD mortality. Conclusion: The prevalence of NAFLD in female NHANES participants from the United States has continued over recent years. In the female population with NAFLD, ASCVD ≥7.5% is an independent predictor of overall and cardiac-specific mortality.

Figures

Figure 1
Figure 1
Prevalence (%) of NAFLD among U.S. female adults, NHANES (1988‐2014). *Indicates the linear trend over time with P < 0.05.

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73‐84.
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221‐1231.
    1. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non‐alcoholic fatty liver disease. Metabolism 2016;65:1017‐1025.
    1. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017;23:8263‐8276.
    1. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore) 2018;97:e0214.
    1. Yki‐Järvinen H. Non‐alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901‐910.
    1. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063‐2072.
    1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330‐344.
    1. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016;20:205‐214.
    1. Kalia HS, Gaglio PJ. The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin Liver Dis 2016;20:215‐224.
    1. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34:1291‐1326.
    1. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646‐650.
    1. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non‐alcoholic fatty liver disease. World J Gastroenterol 2014;20:1724‐1745.
    1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434‐438.
    1. Centers for Disease Control and Prevention ; National Center for Health Statistics . National Health and Nutrition Examination Survey . Documentation files 1988‐1994, 1999‐2000, 2001‐2002, 2003‐2004, 2005‐2006, 2007‐2008, 2009‐2010, 2011‐2012, and 2013‐2014. . Accessed March 1, 2018.
    1. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015;41:65‐76.
    1. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319‐327.
    1. Centers for Disease Control and Prevention, National Center for Health Statistics . Analytic and reporting guidelines: The Third National Health and Nutrition Examination Survey, NHANES III (1988‐94). . Published October 1996. Accessed December 26, 2017.
    1. AACE Task Force for Developing a Diabetes Comprehensive Care Plan Writing Committee . American Association of Clinical Endocrinologists and American College of Endocrinology‐Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan‐2015. Endocr Pract 2015;21(Suppl. 1):1‐87. .
    1. American Heart Association . High blood pressure. . Accessed October 2018.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486‐2497.
    1. Goff DC Jr, Lloyd‐Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl. 2):S49‐S73.
    1. Wolter KM. Introduction to Variance Estimation. 2nd ed New York, NY: Springer; 2007.
    1. Rao JNK, Scott AJ. The analysis of categorical data from complex sample surveys: chi‐squared tests for goodness of fit and independence in two‐way tables. J Am Stat Assoc 1981;76:221‐230.
    1. Rao JNK, Scott AJ. On chi‐squared tests for multiway contingency tables with cell proportions estimated from survey data. Ann Stat 1984;12:46‐60.
    1. National Center for Health Statistics . Office of Analysis and Epidemiology, NCHS 2011 linked mortality files matching methodology. . Published September 2013. Accessed February 14, 2018.
    1. National Center for Health Statistics . NCHS Surveys: 2011 linked mortality files: public‐use data dictionary. . Updated February 24, 2015. Accessed January 10, 2018.
    1. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute, Inc.; 1995.
    1. Souza MR, Diniz Mde F, Medeiros‐Filho JE, Araújo MS. Metabolic syndrome and risk factors for non‐alcoholic fatty liver disease. Arq Gastroenterol 2012;49:89‐96.
    1. Bruno Ade S, Rodrigues MH, Alvares MC, Nahas‐Neto J, Nahas EA. Non‐alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women. Climacteric 2014;17:465‐471.
    1. Ryu S, Suh BS, Chang Y, Kwon MJ, Yun KE, Jung HS, et al. Menopausal stages and non‐alcoholic fatty liver disease in middle‐aged women. Eur J Obstet Gynecol Reprod Biol 2015;190:65‐70.
    1. Rodrigues MH, Bruno AS, Nahas‐Neto J, Sandrim VC, Muniz LG, Nahas EA. Evaluation of clinical and inflammatory markers of nonalcoholic fatty liver disease in postmenopausal women with metabolic syndrome. Metab Syndr Relat Disord 2014;12:330‐338.
    1. Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non‐alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 2015;52:117‐123.
    1. Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health (Lond) 2009;5:191‐203.
    1. Gutierrez‐Grobe Y, Ponciano‐Rodríguez G, Ramos MH, Uribe M, Méndez‐Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402‐409.
    1. Chen KL, Madak‐Erdogan Z. Estrogens and female liver health. Steroids 2018;133:38‐43.
    1. National Center for Health Statistics . Health, United States, 2016: With Chartbook on Long‐Term Trends in Health. Hyattsville, MD: National Center for Health Statistics; 2017.
    1. Dietrich P, Hellerbrand C. Non‐alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014;28:637‐653.
    1. Tarantino G, Finelli C. What about non‐alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013;19:3375‐3384.
    1. Lim HW, Bernstein DE. Risk factors for the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including genetics. Clin Liver Dis 2018;22:39‐57.
    1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015‐2016. NCHS Data Brief 2017;288. .
    1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics‐2017 update: a report from the American Heart Association. Circulation 2017;135:e146‐e603. Erratum in: Circulation 2017;135:e646 and Circulation 2017;136:e196.
    1. Centers for Disease Control and Prevention . National diabetes statistics report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017. .
    1. Chinchilla‐López P, Ramírez‐Pérez O, Cruz‐Ramón V, Canizales‐Quinteros S, Domínguez‐López A, Ponciano‐Rodríguez G, et al. More evidence for the genetic susceptibility of Mexican population to nonalcoholic fatty liver disease through PNPLA3. Ann Hepatol 2018;17:250‐255.
    1. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease‐atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013;19:5177‐5192.
    1. Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012;27:420‐428.
    1. Mellinger JL, Pencina KM, Massaro JM, Hoffmann U, Seshadri S, Fox CS, et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J Hepatol 2015;63:470‐476.
    1. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non‐alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013;62:352‐360.
    1. Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all‐cause mortality and liver‐related mortality in patients with non‐alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58:3017‐3023.
    1. Golabi P, Fukui N, Otgonsuren M, deAvila L, Sayiner M, Younossi ZM. Can atherosclerotic cardiovascular risk score (ASCVD) predict mortality in patients with non‐alcoholic fatty liver disease (NAFLD)? J Hepatol 2017;66(Suppl):S598.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi